Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maura L Gillison

Showing results (131-140 of 153) with videos related to

Pageof 16
Sort By:
Cell Reports. Medicine|January 24, 2025
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targetsLuz Yurany Moreno Rueda, Hua Wang, Keiko Akagi, et al.
Cancer Discovery|January 28, 2021
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor GrowthHubert Lam, Lisa K McNeil, Hanna Starobinets, et al.
JAMA Otolaryngology-- Head & Neck Surgery|December 4, 2025
Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical TrialsLaila A Gharzai, Emily Morris, Matthew J Schipper, et al.
The Lancet. Oncology|February 29, 2024
Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysisLaila A Gharzai, Emily Morris, Krithika Suresh, et al.
International Journal of Radiation Oncology, Biology, Physics|October 13, 2022
Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504Maura L Gillison, Robert L Ferris, Jonathan Harris, et al.
International Journal of Particle Therapy|July 21, 2021
Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution ExperienceG Brandon Gunn, Adam S Garden, Rong Ye, et al.
Lancet (London, England)|November 20, 2018
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialMaura L Gillison, Andy M Trotti, Jonathan Harris, et al.
Cancer Immunology Research|March 19, 2026
FOXM1-specific TCR-engineered T cells target non-small cell lung cancerEmily Bontekoe, Minying Zhang, Peixin Jiang, et al.
Vaccine|November 16, 2013
Comprehensive control of human papillomavirus infections and related diseasesF Xavier Bosch, Thomas R Broker, David Forman, et al.
Vaccine|December 17, 2013
Comprehensive control of human papillomavirus infections and related diseasesF Xavier Bosch, Thomas R Broker, David Forman, et al.
Pageof 16

Showing results (131-140 of 153) with videos related to

Sort By:
Pageof 16
Cell Reports. Medicine|January 24, 2025
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targetsLuz Yurany Moreno Rueda, Hua Wang, Keiko Akagi, et al.
Cancer Discovery|January 28, 2021
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor GrowthHubert Lam, Lisa K McNeil, Hanna Starobinets, et al.
JAMA Otolaryngology-- Head & Neck Surgery|December 4, 2025
Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical TrialsLaila A Gharzai, Emily Morris, Matthew J Schipper, et al.
The Lancet. Oncology|February 29, 2024
Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysisLaila A Gharzai, Emily Morris, Krithika Suresh, et al.
International Journal of Radiation Oncology, Biology, Physics|October 13, 2022
Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504Maura L Gillison, Robert L Ferris, Jonathan Harris, et al.
International Journal of Particle Therapy|July 21, 2021
Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution ExperienceG Brandon Gunn, Adam S Garden, Rong Ye, et al.
Lancet (London, England)|November 20, 2018
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialMaura L Gillison, Andy M Trotti, Jonathan Harris, et al.
Cancer Immunology Research|March 19, 2026
FOXM1-specific TCR-engineered T cells target non-small cell lung cancerEmily Bontekoe, Minying Zhang, Peixin Jiang, et al.
Vaccine|November 16, 2013
Comprehensive control of human papillomavirus infections and related diseasesF Xavier Bosch, Thomas R Broker, David Forman, et al.
Vaccine|December 17, 2013
Comprehensive control of human papillomavirus infections and related diseasesF Xavier Bosch, Thomas R Broker, David Forman, et al.
Pageof 16